November 23, 2018

Juventas Therapeutics Acquired by Astellas

Juventas Therapeutics, a Cleveland developer of regenerative medicine technologies and BioEnterprise client, was acquired by Astellas for an undisclosed amount. The agreement grants Astellas a license to develop JVS-100 through phase 2a clinical studies with an option to acquire the therapy for further development and commercialization.

Read More  >